$SCNX
Scienture Holdings, Inc. Stock $scnx

$scnx Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223009090 Filed on March 27, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$2.248M	$2.529M	$11.45M
YoY Change	-30.63%	5.91%	15.76%
Cost Of Revenue	$690.7K	$986.4K	$5.997M
YoY Change	-63.74%	-14.06%	16.6%
Gross Profit	$1.557M	$1.543M	$5.451M
YoY Change	16.57%	24.38%	14.86%
Gross Profit Margin	69.27%	61.0%	47.62%
Selling, General & Admin	$1.904M	$1.820M	$8.208M
YoY Change	-17.35%	-9.99%	-6.86%
% of Gross Profit	122.31%	118.01%	150.57%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$2.821K	$2.820K	$14.64K
YoY Change	-28.94%	34.29%	99.14%
% of Gross Profit	0.18%	0.18%	0.27%
Operating Expenses	$1.904M	$1.820M	$9.876M
YoY Change	-17.35%	-9.99%	12.07%
Operating Profit	-$347.4K	-$277.8K	-$4.424M
YoY Change	-64.13%	-64.49%	8.82%
Interest Expense	$62.39K	-$183.0K	$336.2K
YoY Change	-4687.65%	8958.91%	-1525.21%
% of Operating Profit
Other Income/Expense, Net	$21.70K	$825.5K	$514.4K
YoY Change	693.02%		-2280.7%
Pretax Income	-$325.7K	-$1.303M	-$3.910M
YoY Change	-66.28%	66.13%	-26.45%
Income Tax
% Of Pretax Income
Net Earnings	-$678.0K	-$925.2K	-$3.472M
YoY Change	-29.81%	17.96%	-34.68%
Net Earnings / Revenue	-30.16%	-36.58%	-30.33%
Basic Earnings Per Share	-$0.07		-$0.41
Diluted Earnings Per Share	-$0.06	-$0.10	-$0.41
COMMON SHARES
Basic Shares Outstanding	10.11M shares	9.319M shares	8.473M shares
Diluted Shares Outstanding	670.7K shares		566.6K shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.194M	$1.134M	$1.134M
YoY Change	-36.17%	-63.7%	-63.7%
Cash & Equivalents	$1.200M	$1.100M
Short-Term Investments
Other Short-Term Assets	$357.9K	$110.9K	$110.9K
YoY Change	-13.04%	-48.74%	-48.74%
Inventory	$126.3K	$119.6K	$119.6K
Prepaid Expenses	$357.9K	$110.9K
Receivables	$707.9K	$729.0K	$729.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.386M	$2.093M	$2.093M
YoY Change	-33.67%	-52.15%	-52.15%
LONG-TERM ASSETS
Property, Plant & Equipment	$62.39K	$65.21K	$1.117M
YoY Change	-95.02%	-33.96%	-16.13%
Goodwill		$0.00
YoY Change
Intangibles		$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$49.03K	$49.03K	$49.03K
YoY Change	0.0%	-18.47%	-18.47%
Total Long-Term Assets	$1.652M	$1.617M	$1.617M
YoY Change	-26.37%	16.16%	16.16%
TOTAL ASSETS
Total Short-Term Assets	$2.386M	$2.093M	$2.093M
Total Long-Term Assets	$1.652M	$1.617M	$1.617M
Total Assets	$4.038M	$3.710M	$3.710M
YoY Change	-30.86%	-35.66%	-35.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$515.8K	$729.2K	$729.2K
YoY Change	-43.23%	52.85%	52.85%
Accrued Expenses	$303.2K	$290.0K	$486.9K
YoY Change	-41.71%	7.24%	8.44%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$166.7K	$166.7K
YoY Change	-100.0%
Total Short-Term Liabilities	$2.550M	$2.147M	$2.147M
YoY Change	59.75%	131.83%	131.83%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$333.3K	$333.3K
YoY Change	-100.0%
Other Long-Term Liabilities	$832.5K	$887.0K	$887.0K
YoY Change	-18.62%	-17.1%	-17.1%
Total Long-Term Liabilities	$832.5K	$887.0K	$1.220M
YoY Change	-38.62%	-17.1%	14.06%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.550M	$2.147M	$2.147M
Total Long-Term Liabilities	$832.5K	$887.0K	$1.220M
Total Liabilities	$3.383M	$3.367M	$2.947M
YoY Change	13.89%	68.7%	47.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$19.90M	-$19.70M
YoY Change		21.25%
Common Stock	$100.00	$99.00
YoY Change		20.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$655.1K	$763.1K	$763.1K
YoY Change
Total Liabilities & Shareholders Equity	$4.038M	$3.710M	$3.710M
YoY Change	-30.86%	-35.66%	-35.66%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$678.0K	-$925.2K	-$3.472M
YoY Change	-29.81%	17.96%	-34.68%
Depreciation, Depletion And Amortization	$2.821K	$2.820K	$14.64K
YoY Change	-28.94%	34.29%	99.14%
Cash From Operating Activities	-$931.5K	$1.230M	-$1.526M
YoY Change	-6.92%	-388.26%	-40.54%
INVESTING ACTIVITIES
Capital Expenditures	$87.07K	$115.0K
YoY Change		-608.63%
Acquisitions
YoY Change
Other Investing Activities	$420.3K	$0.00	$23.00K
YoY Change	1727.26%
Cash From Investing Activities	$333.2K	-$115.0K	-$427.8K
YoY Change	1348.68%	408.63%	1793.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$130.9K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$681.3K	-303.2K	-$35.17K
YoY Change	-348.52%		-83.11%
NET CHANGE
Cash From Operating Activities	-$931.5K	1.230M	-$1.526M
Cash From Investing Activities	$333.2K	-115.0K	-$427.8K
Cash From Financing Activities	$681.3K	-303.2K	-$35.17K
Net Change In Cash	$82.92K	811.9K	-$1.989M
YoY Change	-106.62%	-280.7%	-28.89%
FREE CASH FLOW
Cash From Operating Activities	-$931.5K	$1.230M	-$1.526M
Capital Expenditures	$87.07K	$115.0K
Free Cash Flow	-$1.019M	$1.115M	-$1.526M
YoY Change		-375.93%	-40.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001382574
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Auditor Firm AuditorFirmId	206
CY2021Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill		usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent		usd
CY2021Q4	MEDS	Contingent Funding Liabilities ContingentFundingLiabilities		usd
CY2021Q4	MEDS	Warrant Liability WarrantLiability		usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent		usd
CY2021Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest		usd
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
CY2022	MEDS	Loss On Writedown Of Inventory LossOnWritedownOfInventory		usd
CY2021	MEDS	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability		usd
CY2021	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
CY2022	MEDS	Loss On Inventory Investments LossOnInventoryInvestments		usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets		usd
CY2021	MEDS	Increase Decrease In Current Liabilities IncreaseDecreaseInCurrentLiabilities		usd
CY2021	MEDS	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability		usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability		usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2021	us-gaap	Payments For Software PaymentsForSoftware		usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2021	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities		usd
CY2021	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders		usd
CY2021	MEDS	Proceeds From Sale Of Future Revenue ProceedsFromSaleOfFutureRevenue		usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2021	MEDS	Insurance Premium Financed InsurancePremiumFinanced		usd
CY2021	us-gaap	Notes Issued1 NotesIssued1		usd
CY2021	MEDS	Intangible Asset Contribution From Non Controlling Interest IntangibleAssetContributionFromNonControllingInterest		usd
CY2022	MEDS	Loss On Writedown Of Inventory LossOnWritedownOfInventory		usd
CY2021	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instrument For Feited Expired Cancelled Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentForFeitedExpiredCancelledIntrinsicValue		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-39199
CY2022	dei	Entity Registrant Name EntityRegistrantName	TRxADE HEALTH, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-3673928
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	2420 Brunello Trace.
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Lutz
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33558
CY2022	dei	City Area Code CityAreaCode	(800)
CY2022	dei	Local Phone Number LocalPhoneNumber	261-0281
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 Par Value Per Share
CY2022	dei	Trading Symbol TradingSymbol	MEDS
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	16921890	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10110878	shares
CY2022	dei	Auditor Name AuditorName	MaloneBailey, LLP
CY2022	dei	Auditor Location AuditorLocation	Houston, Texas
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1133633	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3122578	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	728964	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	978973	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	119582	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	56279	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	110944	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	216414	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2093123	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	4374244	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	65214	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	98751	usd
CY2022Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	450845	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	763136	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3770173	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	49029	usd
CY2021Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	60136	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1051815	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1233033	usd
CY2022Q4	us-gaap	Assets Assets	3710026	usd
CY2021Q4	us-gaap	Assets Assets	5766164	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	729153	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	477028	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	290013	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	270437	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	67517	usd
CY2022Q4	MEDS	Contingent Funding Liabilities ContingentFundingLiabilities	108036	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	196872	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	178561	usd
CY2022Q4	MEDS	Warrant Liability WarrantLiability	588533	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	166667	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2146791	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	926026	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	887035	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1069965	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	333333	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3367159	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1995991	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9393708	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9393708	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8166457	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8166457	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	99	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	82	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	20482573	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	20017528	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19719536	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16247437	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-420269	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	342867	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3770173	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3710026	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5766164	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11448265	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9889433	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5997049	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5143468	usd
CY2022	us-gaap	Gross Profit GrossProfit	5451216	usd
CY2021	us-gaap	Gross Profit GrossProfit	4745965	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	792500	usd
CY2022	MEDS	Loss On Inventory Investment LossOnInventoryInvestment	875250	usd
CY2021	MEDS	Loss On Inventory Investment LossOnInventoryInvestment	1226426	usd
CY2021	MEDS	Loss On Writedown Of Inventory LossOnWritedownOfInventory	376348	usd
CY2022	us-gaap	Salaries And Wages SalariesAndWages	3941475	usd
CY2021	us-gaap	Salaries And Wages SalariesAndWages	3846522	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	519642	usd
CY2021	us-gaap	Professional Fees ProfessionalFees	1094917	usd
CY2022	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	830355	usd
CY2021	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	697825	usd
CY2022	MEDS	Technology Expense TechnologyExpense	1160856	usd
CY2021	MEDS	Technology Expense TechnologyExpense	899705	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1755433	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1896515	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	9875511	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	10038258	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-4424295	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-5292293	usd
CY2022	MEDS	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	825544	usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	20989	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	4100	usd
CY2022	us-gaap	Interest Expense InterestExpense	336206	usd
CY2021	us-gaap	Interest Expense InterestExpense	23590	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	514427	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-23590	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-3909868	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-5315883	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3472099	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-5315883	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-437769	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.41
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8472946	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8136740	shares
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8679158	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	181163	usd
CY2021	MEDS	Stock Issued During Period Value Warrants Exercised For Cash StockIssuedDuringPeriodValueWarrantsExercisedForCash	15001	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	21640	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1821	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	187273	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-5315883	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3770173	usd
CY2022	MEDS	Noncontrolling Interest Of Capital Contributions NoncontrollingInterestOfCapitalContributions	792500	usd
CY2022	MEDS	Noncontrolling Interest Of Capital Distributions NoncontrollingInterestOfCapitalDistributions	-775000	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	254106	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	130918	usd
CY2022	MEDS	Stock Issued During Period Value Warrants Exercised For Cash StockIssuedDuringPeriodValueWarrantsExercisedForCash	875	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	79163	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-3909868	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	342867	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-3909868	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-5315883	usd
CY2022	us-gaap	Depreciation Depreciation	14637	usd
CY2021	us-gaap	Depreciation Depreciation	7351	usd
CY2022	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	79163	usd
CY2021	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	187273	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	254106	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	181163	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-246683	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	615657	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	21640	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	792500	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	875250	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	376348	usd
CY2021	MEDS	Loss On Inventory Investments LossOnInventoryInvestments	143891	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	4100	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	181218	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	131558	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-496692	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	789587	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-336928	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	103666	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	63303	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-825127	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	875250	usd
CY2021	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-1087675	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-164618	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-131153	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	252125	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	220199	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-200776	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-13819	usd
CY2022	MEDS	Increase Decrease In Current Liabilities IncreaseDecreaseInCurrentLiabilities	67517	usd
CY2022	MEDS	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	588533	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-10000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1525929	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2566226	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22596	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	23000	usd
CY2022	us-gaap	Payments For Software PaymentsForSoftware	450845	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-427845	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22596	usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	225000	usd
CY2022	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	716964	usd
CY2022	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	275000	usd
CY2022	MEDS	Proceeds From Sale Of Future Revenue ProceedsFromSaleOfFutureRevenue	825000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1821	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	875	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	15001	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	130918	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-35171	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-208178	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1988945	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2797000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3122578	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5919578	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1133633	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3122578	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	336206	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	28337	usd
CY2022	MEDS	Insurance Premium Financed InsurancePremiumFinanced	220354	usd
CY2022	us-gaap	Notes Issued1 NotesIssued1	500000	usd
CY2022	MEDS	Intangible Asset Contribution From Non Controlling Interest IntangibleAssetContributionFromNonControllingInterest	792500	usd
CY2019Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	range from one-for-two (1-for-2) to one-for-ten (1-for-10)
CY2020Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	stock split ratio of 1-for-6
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	44100	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	792000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.41
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19700000	usd
CY2022Q4	MEDS	Working Capital WorkingCapital	54000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1100000	usd
CY2022	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	1500000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84C_eus-gaap--UseOfEstimates_zSi5M0QwIkVg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_ziarkC8JjqO4">Use of Estimates</span></i></b> – In preparing these financial statements, management is required to make estimates and assumptions that effect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84B_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zwXUsB70yCF8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86E_zH9UzklpAKYh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reclassification </i></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">– Certain prior year amounts have been reclassified to conform to the current year presentation. The reclassification did not result in a change in the net loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1407276	shares
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-246683	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	615657	usd
CY2022	us-gaap	Allowance For Loan And Lease Loss Recovery Of Bad Debts AllowanceForLoanAndLeaseLossRecoveryOfBadDebts	247861	usd
CY2021	us-gaap	Allowance For Loan And Lease Loss Recovery Of Bad Debts AllowanceForLoanAndLeaseLossRecoveryOfBadDebts	247861	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	usd
CY2021	MEDS	Loss On Writedown Of Inventory LossOnWritedownOfInventory	376348	usd
CY2021Q4	us-gaap	Goodwill Goodwill	0	usd
CY2022Q4	us-gaap	Goodwill Goodwill	0	usd
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	792000	usd
CY2022	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P15Y
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	1	pure
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2663045	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2689969	shares
CY2022Q4	MEDS	Number Of Options Outstanding NumberOfOptionsOutstanding	295623	shares
CY2022	us-gaap	Profit Loss ProfitLoss	-3909868	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-5315883	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3472099	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5315883	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8472946	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8136740	shares
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zO2xMndYd6i6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zjEvOgraI604">Concentration of Credit Risks and Major Customers</span></i></b> - Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and receivables. The Company places its cash and cash equivalents with financial institutions. Deposits are insured to Federal Deposit Insurance Corp limits. The amount of cash not insured by the FDIC as of December 31, 2022 is $<span id="xdx_90A_eus-gaap--CashUninsuredAmount_iI_pp0p0_c20221231_zJ58bmXMuKg2" title="Cash, uninsured amount">518,419</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2022, no sales to customers represented greater than <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomersMember_zHYKp5CCSXpg" title="Concentration risk, percentage">10</span>% of revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	518419	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	14584	shares
CY2022Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	875	usd
CY2021Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	5000	shares
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.00
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.00
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5000	shares
CY2021Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	15000	usd
CY2022	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	0	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	82751	shares
CY2020Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	1.33
CY2021	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Beginning ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning	P2Y8M23D
CY2020Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instrument Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentOutstandingIntrinsicValue	352951	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	5000	shares
CY2021	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice	3.00
CY2021	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageRemainingContractualTerm	P1Y5M23D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	38216	shares
CY2021	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeited In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice	2.51
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	5000	shares
CY2021	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice	3.00
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	44535	shares
CY2021Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.32
CY2022	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Beginning ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning	P0Y11M12D
CY2021Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instrument Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentOutstandingIntrinsicValue	208078	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	2663045	shares
CY2022	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice	1.50
CY2022	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageRemainingContractualTerm	P4Y9M7D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	3027	shares
CY2022	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeited In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice	3.90
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	14584	shares
CY2022	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice	0.06
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	2689969	shares
CY2022Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	1.50
CY2022	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Ending ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding	P4Y8M19D
CY2022Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instrument Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentOutstandingIntrinsicValue	6731	usd
CY2022Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisableNumber	2689969	shares
CY2022Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	1.50
CY2022	MEDS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityExercisableWeightedAverageRemainingContractualTerm1	P4Y8M19D
CY2022Q4	MEDS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityExercisableIntrinsicValue1	6731	usd
CY2021	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	168008	usd
CY2020	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	557308	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.0025	pure
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2022	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	79163	usd
CY2021	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	187273	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	29729	usd
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P5Y
CY2017Q4	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4030755	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2347266	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4030755	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2347266	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	17105445	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1069965	usd
CY2022Q4	MEDS	Lease Obligation Current LeaseObligationCurrent	195475	usd
CY2022Q4	MEDS	Operating Lease Liabilities Noncurrent OperatingLeaseLiabilitiesNoncurrent	874490	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	13943	usd
CY2021Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	630000	usd
CY2022	MEDS	Attorney Fees AttorneyFees	630000	usd
CY2021Q3	MEDS	Bad Debt Expenses BadDebtExpenses	630000	usd
CY2022Q2	MEDS	Attorney Fees AttorneyFees	743000	usd
CY2022	MEDS	Bad Debt Expenses BadDebtExpenses	248000	usd
CY2022	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p id="xdx_80C_eus-gaap--LossContingencyDisclosures_zRTbgjzeMQE9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="L1_001"/>NOTE 10 – <span id="xdx_829_z7X8PagAwtk5">CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Studebaker Defense Group, LLC</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2020, the Company’s wholly-owned subsidiary, Integra Pharma Solutions, LLC (“Integra”), entered into an agreement with Studebaker Defense Group, LLC (“Studebaker”) wherein Integra would pay Studebaker a down payment of $<span id="xdx_908_ecustom--DownPayment_c20200701__20200731__dei--LegalEntityAxis__custom--IntegraMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember_zpUit57jH351" title="Down payment">500,000</span> and Studebaker would deliver <span id="xdx_90D_ecustom--NumberOfNitrileGlovesDelivered_uInteger_c20200813__20200814__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember__dei--LegalEntityAxis__custom--IntegraMember_zYSCcVLOXjOl" title="Number of nitrile gloves delivered">180,000</span> boxes of nitrile gloves by August 14, 2020. Integra wired the $<span id="xdx_90A_eus-gaap--LossContingencyDamagesSoughtValue_c20200701__20200731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember__dei--LegalEntityAxis__custom--IntegraMember_z97KZnjOXsDj" title="Loss contingency, damages sought, value">500,000</span> to Studebaker, but to date, Studebaker has not delivered the gloves or provided a refund of the deposit. In December 2020, we filed a complaint against Studebaker in Florida state court, Case No. 20-CA-010118 in the Circuit Court for the Thirteenth Judicial Circuit in Hillsborough County, for among other things, breach of contract. Studebaker did not answer the complaint, nor did counsel for Studebaker file an appearance. Accordingly, in February 2021, the Company filed for a default judgment; however, on March 22, 2021, counsel for Studebaker filed an appearance and shortly thereafter filed a motion to vacate the default judgment and dismiss the complaint on jurisdictional grounds. The court granted Studebaker’s motion to set aside the default judgment but denied the motion to dismiss. The Company has filed several pretrial motions; the next step in the litigation after the pre-trial motions are resolved will be a motion for summary judgment. The Company believes it will prevail on the merits but cannot determine the timing of the judgment or the amount ultimately collected. At June 30, 2021, the $<span id="xdx_906_ecustom--LossOnInventoryInvestment_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember__dei--LegalEntityAxis__custom--IntegraMember_zbAKDMFI2ab6" title="Loss on inventory investment">500,000</span> was recorded as Loss on Inventory Investment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sandwave Group Dsn Bhd and Crecom Burj Group SDN BHD</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, Integra, entered into an agreement with Sandwave Group Dsn Bhd (“Sandwave”), wherein Integra would pay Sandwave a down payment of $<span id="xdx_909_ecustom--DownPayment_c20200801__20200831__dei--LegalEntityAxis__custom--IntegraMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember_zP5z4Dwz6TU9" title="Down payment">581,250</span> and Sandwave’s supplier, Crecom Burj Group SDN BHD (“Crecom”), would deliver <span id="xdx_905_ecustom--NumberOfNitrileGlovesDelivered_uInteger_c20200801__20200831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember__dei--LegalEntityAxis__custom--IntegraMember_zAzJEeNIsEPg" title="Number of nitrile gloves delivered">150,000</span> boxes of nitrile gloves within 45 days. Integra wired the $<span id="xdx_902_eus-gaap--LossContingencyDamagesSoughtValue_c20200801__20200831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember__dei--LegalEntityAxis__custom--IntegraMember_zHgNcNuf0jIe" title="Loss contingency damages sought value">581,250</span> to Sandwave, which in turn wired the purchase price to Crecom, which Crecom accepted; however, to date, Crecom has not delivered the nitrile gloves. Integra demanded return of its $<span id="xdx_904_eus-gaap--LossContingencyDamagesSoughtValue_c20200801__20200831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CrecomBurjGroupSdnBhdMember__dei--LegalEntityAxis__custom--IntegraMember_zVIuBsawdGMd" title="Loss contingency damages sought value">581,250</span> and Crecom has acknowledged that Integra is entitled to a refund, but to date Crecom has failed to return Integra’s money. In February 2021, Integra filed a complaint against Crecom in Malaysia: Case No. WA-22NCC-55-02/2021 in the High Court of Malaysia at Kuala Lumpur in the Federal Territory, Malaysia for the Malaysian equivalent of breach of contract. Crecom filed an appearance on March 1, 2021. In April 2021, an Application for Summary Judgment was filed with the court, and on May 25, 2021, the Court extracted the sealed application, and a copy thereof was served on Crecom’s attorneys and Crecom, 14 days later, filed an Affidavit in Reply with the court alleging that there are issues to be tried and that this case must go to a full trial. On June 28, 2021, the court directed both parties to file their written submissions/arguments in relation to the application for summary judgment on or before July 12, 2021, and scheduled a hearing thereon for August 26, 2021. At the final hearing on October 18, 2021, the ruling for the summary judgment was denied. On September 1, 2022, Crecom informed the court that Crecom had been liquidated pursuant to Malaysian insolvency laws and the court proceedings were stayed. ON September 7, 2022, Integra received written confirmation from Crecom counsel and a copy of the relevant Winding Up Order. Accordingly, the complaint was dismissed. At June 30, 2021, the $<span id="xdx_90F_ecustom--LossOnInventoryInvestment_c20210101__20210630__dei--LegalEntityAxis__custom--IntegraMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember_zhhAfrWIiEo7" title="Loss on inventory investment">581,250</span> was recorded as Loss on Inventory Investment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Jain, et al., v. Memantine, et al.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2020, we became aware of a complaint filed by Jitendra Jain, Manish Arora, Scariy Kumaramangalam, Harsh Datta and Balvant Arora (collectively, plaintiffs), against our wholly-owned subsidiary, Trxade, Inc. and our Chief Executive Officer, Suren Ajjarapu as well as certain unrelated persons, Annapurna Gundlapalli, Gajan Mahendiran and Nexgen Memantine (collectively, defendants), in the Circuit Court of Madison County, Alabama (Case:47-CV-2019-902216.00). The complaint alleged causes of actions against the defendants including fraud in the inducement, relating to certain investments alleged to have been made by plaintiffs in Nexgen Memantine, breach of fiduciary duty, conversion and voidable transactions. The complaint related to certain investments alleged made by the plaintiffs in Nexgen Memantine and certain alleged fraudulent transfers of assets and funds alleged to have been taken by the defendants which are unrelated to the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 14, 2021, Plaintiffs filed a second amended complaint against the defendants. The second amended complaint alleges causes of action against the defendants including securities fraud, breach of fiduciary duty, violation of the Florida RICO Act, and breach of contract. The operative complaint relates to certain investments alleged to have been made by the plaintiffs in Nexgen Memantine and certain alleged transfers of assets and funds alleged to have been taken by the defendants which are unrelated to the Company. The amended complaint seeks injunctive relief, $<span id="xdx_90E_eus-gaap--LossContingencyDamagesPaidValue_c20210501__20210514_zEIpKcsEjil8" title="Compensatory amount value">425,000</span> in compensatory damages, treble damages, punitive damages, and fees and costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2022, a settlement as to Suren Ajjarapu, Annapurna Gundlapalli and the Company was reached and signed. This settlement involved no admission of liability and a full and complete release of all actions after a lump-sum payment of $<span id="xdx_90E_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_c20220201__20220228_zfBFz38nR8P" title="Settlement payment amount">225,000</span> was made. Because the complaint purports to be a derivative action, court approval was required, which approval was received on March 14, 2022. As a result of the settlement, the Plaintiff’s dismissed their lawsuit with prejudice.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q2	us-gaap	Loss Contingency Damages Paid Value LossContingencyDamagesPaidValue	425000	usd
CY2022Q1	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	225000	usd
CY2022Q4	MEDS	Increase In Right Of Use Asset IncreaseInRightOfUseAsset	977220	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	293683	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	302494	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	311569	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	320916	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	105531	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1334193	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	264228	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	181218	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	131558	usd
CY2022	MEDS	Payment For Operating Lease Liabilities PaymentForOperatingLeaseLiabilities	164618	usd
CY2021	MEDS	Payment For Operating Lease Liabilities PaymentForOperatingLeaseLiabilities	131153	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11448265	usd
CY2022	us-gaap	Gross Profit GrossProfit	5451216	usd
CY2022Q4	us-gaap	Assets Assets	3710026	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-3909868	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	5997049	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9889433	usd
CY2021	us-gaap	Gross Profit GrossProfit	4745965	usd
CY2021Q4	us-gaap	Assets Assets	5766164	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-5315883	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	5143468	usd

Files In Submission

Name	View Source	Status
0001493152-23-009090-index-headers.html	Edgar Link	pending
0001493152-23-009090-index.html	Edgar Link	pending
0001493152-23-009090.txt	Edgar Link	pending
0001493152-23-009090-xbrl.zip	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
form10-k_002.jpg	Edgar Link	pending
meds-20221231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
meds-20221231_cal.xml	Edgar Link	unprocessable
meds-20221231_def.xml	Edgar Link	unprocessable
meds-20221231_lab.xml	Edgar Link	unprocessable
meds-20221231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SCNX
Scienture Holdings, Inc. Stock $scnx

2023 Q1 Form 10-K Financial Statement

#000149315223009090 Filed on March 27, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SCNX Scienture Holdings, Inc. Stock $scnx

2023 Q1 Form 10-K Financial Statement

#000149315223009090 Filed on March 27, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SCNX
Scienture Holdings, Inc. Stock $scnx